Article Details
Retrieved on: 2025-03-21 17:18:47
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
REGENXBIO's DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial ... One of the patients, who ...
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here